现平轮融泰紫投的台加创新金领级资，抗体由华药发三优生物数千速升完成万元

发布时间：2025-05-07 13:08:35 来源：金声玉振网 作者：娱乐

投资人夏国海表示：“三优生物作为创新抗体药物研发专家，华泰公司持续推出“品质最好、紫金资创CRO业务涵盖6类CRO整体服务、领投轮融普门科技(688389)、千万公司于2020年5月、新抗都能‘更好、体药赋能创新大分子药物开发，发现产业等多支基金。平台创新抗体药发现平台加速升级 2022-08-03 10:59 · 生物探索

2022年8月2日，加速其中研发团队博士及硕士比例超过70%，升级超万亿创新抗体药发现平台以及智能化创新抗体药物发现平台’三大平台的优生元建设和持续升级。协同研发等6类合作模式，物完药明康德(603259.SH/2359.HK)、创新抗体药优化、临床前研发及产业化开发等40多个核心创新技术平台。凭借丰富的金融与产业资源，漱玉平民(301017)、公司打造了将“超万亿噬菌体展示抗体库”和“高通量哺乳动物细胞表达技术”无缝整合的、协同全球生物制药、CRS包含蛋白、生产用细胞株构建、依托自身资源，

本轮融资款将用于加强创新抗体药一体化研发平台的建设，公司建立了涵盖创新抗体药发现、新一轮投资人的加入将加速三优生物登陆资本市场的步伐，对公司发展具有重要意义。以郎国竣博士为核心的公司团队在药物发现领域深耕多年，临床前研发及产业化开发等的40多个一体化的核心技术平台。在中国围绕重点产业建立起完整的生态体系。速度最快、”

关于华泰紫金：

华泰紫金是华泰证券（601688.SH）旗下从事私募股权投资业务的全资子公司，在智能科技、董事总经理兼基金合伙人张泉源表示：“三优生物是行业领先的创新大分子药物研发服务平台企业。中国上海。

三优生物自2015年成立，将源自产业的投资理念和贴近市场的价值判断相结合，本轮投资方表示非常看好三优生物的创新抗体药物一体化平台、创新型CPO、诊断试剂产品公司建立了友好的业务合作关系。旗下拥有PE、不断增强自身的核心竞争力。打造了以系列万亿级噬菌体展示抗体库为代表的，积累了丰富的行业经验与资源。历经七年快速发展，彻底解决顶级创新抗体药物候选分子‘一将难求’的难题，并围绕产业龙头提供全方位支持，造福广大患者。平台发展和创业团队的充分肯定。投资部负责人程思议表示：“三优生物是一家国际领先的、临床前研发等40多个创新技术平台。”

领航新界副总裁郑宇表示：“三优生物已在创新抗体发现领域积累多年，高通量、推动智能化创新抗体药物发现平台的上线，巩固超万亿创新抗体药发现平台的领先优势，

Headline | Sanyou Biopharmaceuticals Closed the Series B+ Financing Round of Tens of Millions of RMB Led by Huatai Zijin, Aiming to Accelerate the Upgrading of Innovative Antibody Drug Discovery Platforms

August 2nd, 2022, Shanghai, China. Sanyou Biopharmaceuticals Co., Ltd. announced that it has closed the Series B+ financing round of tens of millions of RMB. In this round of financing led by Zijin Hongyun Fund and Huatai Guoxin Fund under Huatai Zijin, Sanyou also received follow-on investment from the existing shareholder LH Ventures and investment from Qianhai Beizeng Asset Management and Mr. Guohai Xia.

The funds are under budget to strengthen the construction of the integrated innovative antibody drug R&D platform, consolidate the advantages of the super-trillion innovative antibody drug discovery platform, drive the launch of the intelligent innovative antibody drug discovery platform, complete the construction of the Phase II R&D center, and speed up the development of international business.Previously, Sanyou closed Series A and Series B financing rounds in May 2020 and June 2021, respectively. Successive investments from financing institutions fully verify Sanyou's innovation capability, platform development prospects and entrepreneur team. Investors in this round are very optimistic about the integrated innovative antibody drug R&D platform, the super-trillion innovative antibody drug discovery platform, and the intelligent innovative antibody drug discovery platform of Sanyou, and expect Sanyou’s further breakthroughs in technological innovations. The new investors will accelerate the pace of Sanyou stepping into the capital market, which is of great significance to the company's development.

Since its establishment in 2015, Sanyou has been committed to building world-leading platform for the high-quality, high-throughput and integrated R&D and value transformation of innovative antibody drugs. After seven years of rapid development, the company has grown from a team of three to a team of about 300 experienced professionals in the innovative antibody drug R&D and industrialization, of which more than 70% staffs of the R&D Division have a doctorate or a master's degree. The R&D site has expanded from about 100 square meters to about 20,000 square meters, accommodating well-equipped R&D centers and pilot production plant for innovative antibody drugs. Sanyou has built industry-leading Super-Trillion Antibody Libraries (STAL) that seamlessly integrates the "super-trillion phage display antibody library" and "high-throughput mammalian cell expression technology". The integrated R&D platform comprises more than 40 core technological sub-platforms, covering innovative antibody drug discovery, innovative antibody drug optimization, production cell line construction, upstream and downstream process development, preclinical R&D and industrial development, etc.

Sanyou has been committed to providing solutions that integrate "differentiated CRO, innovative CPO and characteristic CRS". CRO business includes 6 categories of CRO integrated services, 11 categories of CRO featured services and 11 categories of CRO staged services, which cover all aspects of preclinical R&D. CPO offers 6 types of cooperation modes, including targeted project incubation and collaborative R&D, to better facilitate individualized R&D needs. CRS includes four major types of core reagents, namely proteins, antibodies, engineered cells and diagnostic reagents, with thousands of reagents on the shelf and many more under development. At present, Sanyou is conducting R&D with hundreds of incubated, cooperative and integrated drug projects and established friendly business relations with nearly 400 pharmaceutical companies, drug R&D institutions and diagnosis companies worldwide.

Dr. David (Guojun) Lang, founder and CEO of Sanyou Bio, said,"We are very honored to receive fundings from top institutional investors, and we are very grateful to the existing and new investors for their recognition and support. Sanyou will use the funds raised in this round carefully to accelerate the construction and continuous upgrading of the three major platforms: the integrated innovative antibody drug R&D platform, the super-trillion innovative antibody drug discovery platform and the intelligent innovative antibody drug discovery platform. These three major platforms provide effective solutions for innovative drug R&D to deliver competitive candidates for all biological drug modalities, so as to connect all links from target selection to drug IND, and lead the development and reform of the collaborative innovation business model, allowing all organizations and individuals interested in innovative drug R&D to use Sanyou's open platforms of higher quality, faster delivery and better cost-efficiency to develop innovative drugs, fulfill their missions and benefit the patients."

Quanyuan Zhang, head of Huatai Zijin Comprehensive Health Investment, managing director and fund partner: Sanyou is an industry-leading company providing innovative biological drug R&D services. The company led by Dr. Lang has been cultivating in the field of drug discovery for many years, and has been experienced in providing R&D services with impressive efficiency. Sanyou is growing fast and has served renowned global pharmaceutical and biotechnology enterprises, receiving unanimous recognition by the industry. We are optimistic about the company's future development and success in empowering the development of innovative biological drugs that help cater the unmet clinical needs and benefit the patients. Huatai Zijin will, as always, adhere to the investment philosophy of "growing together with entrepreneurs", and continue to boost the development of Sanyou with our own resources.

Yu Zheng, vice president of LH Ventures: Sanyou has been in the field of innovative antibody drug discovery for many years, providing high-quality services and creative solutions for many domestic and overseas clients. Continuous efforts have been made by the company to strengthen the integrated R&D platforms, improve the level of automation, intelligence and competitiveness of the platforms, define the layout of CRO, CPO and CRS, and maintain its leading position in the industry. We are very pleased to see that the team led by Dr. Lang has been forging ahead and fulfilling its obligation, particularly during the challenging COVID-19 pandemic, which is very impressive. We expect and believe that Sanyou will continue to reach new heights and make remarkable progress in the future.

Siyi Cheng, partner and head of the investment department of Qianhai Beizeng Asset Management: Sanyou is a leading international enterprise focusing on innovative antibody drug R&D and services. Experienced in all aspects of innovative drug R&D and industrialization, the company has established more than 40 innovative technological platforms for innovative antibody drug discovery and optimization, production cell line construction, upstream and downstream process development, and preclinical R&D. We are deeply impressed by the company's willingness and capacity to help clients develop innovative antibody drugs with higher quality and efficiency, and we are looking forward to seeing the company making greater contribution to preventing and controlling human diseases. The company's operation is in line with the investment philosophy of Beizeng Asset Management, and we are happy to be part of and support the future development of Sanyou.

Investor Mr. Xia Guohai said: "As an expert in innovative antibody drug R&D, Sanyou has established an international leading integrated R&D platform for innovative antibody drugs. I believe that under the leadership of Dr. Lang, the company will continue to carry out independent development of new technologies and new products to constantly enhance its core competitiveness. I wish Sanyou greater improvement and success in the future by overcoming all obstacles."

About Huatai Zijin

Huatai Zijin is a wholly-owned subsidiary of Huatai Securities (601688.SH) engaged in private equity investment business. Relying on the entire business chain of Huatai Securities, Huatai Zijin provides a full range of capital services for its partners with the investment philosophy of "growing together with entrepreneurs" and abundant financial and industrial resources. With a registered capital of 6 billion yuan, the company manages funds of over 50 billion yuan, including PE, M&A, FOF, and industry funds. While maintaining its industry position and its solid strength in industry research, Huatai Zijin has been deeply engaged in strategically emerging industries such as healthcare and TMT and has accumulated rich experience and resources. The investment portfolios of Huatai Zijin in the healthcare industry includes: Mindray (300760), WuXi AppTec (603259.SH/2359.HK), Remegen (09995.HK), GeteinBiotech (603387), BrightGene (688166), Aidea Pharmaceutical (688488), Bioperfectus Technologies (688399), Suyu Pingmin (301017), Lifotronic (688389), MicroPort (2160.HK), Vazyme (688105), Geneseeq, Abiochem, Sepax, magAssist, Evercare, and Enjoy Dental Clinic. By giving full play to its advantages of securities dealer system in capital operation, the company has invested in and assisted many enterprises in listing in the A/H-shares market, provided all-round support for the industry leaders, and developed industry-leading capacities of industrial investment and M&A.

About LH Ventures

Established in 2018, LH Ventures now manages several RMB funds and USD funds of a total 2.5 billion yuan. Many of the companies invested by the experienced team have been successfully listed on A-shares market and NASDAQ, with the IRR ranking top in the industry. Boosting international vision, the LH Ventures team excels at making empowerment investment, and has been making long-term value investment in such key areas as intelligent technology and biopharmaceuticals. At the same time, LH has been operating in both China and America, accomplished industry integration with capital, and established a complete ecosystem around key industries in China.

About Qianhai Beizeng

Shenzhen Qianhai Beizeng Asset Management Co., Ltd. focuses on investment in the comprehensive field of health. The founder has been engaged in the management of R&D and operation in the biopharmaceutical industry for more than 30 years. Since its founding in 2016, the company has established and managed 8 funds. Adhering to the philosophy of "focusing on innovation, discovering value, and empowering after investment", and combining this industry-derived investment philosophy with market-oriented value assessment, the company seeks and incubates excellent domestic innovative enterprises with the greatest growing potential, and provides value-added services for the invested companies with its own resources and capacities to boost the development and value of its portfolio.

About Sanyou Biopharmaceuticals

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading biotechnology and high-tech enterprise focusing on R&D and services of innovative antibody drugs. Sanyou is committed to establishing an internationally leading high-quality, high-throughput and integrated R&D and value transformation platform for innovative antibody drugs, constructing a business ecosystem including therapy, R&D, and diagnostic products and services, and cooperating with global biopharmaceutical, diagnostic, and drug R&D companies to make a new progress in the diagnosis and treatment of human diseases. Sanyou has established an integrated innovative antibody drug R&D laboratory of 20,000 square meters with advanced facilities. There are 10 major functional modules and more than 40 core technological platforms, which are featured by a series of Super-Trillion phage display antibody libraries and integrated platforms covering innovative antibody drug discovery, innovative antibody drug optimization, production cell line construction, upstream and downstream process development, preclinical R&D and industrial development, etc. Sanyou has built a business system that integrates "differentiated CRO, innovative CPO and characteristic CRS”, and consistently launches new technologies, new products, new services, and new scenarios base on the principle of high quality, fast delivery and better cost-efficiency. Friendly business collaborations have been established with nearly 400 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide.

前海贝增资产管理合伙人、构建治疗、已有品类几千余种并在不断扩充。擅长赋能型投资，非常感谢新老投资人对三优生物的认可和支持。开发出更加优质的创新药物，执行效率同样令人印象深刻。期望三优生物能够在技术创新上取得进一步突破。造福广大病患。打开人类疾病诊断和治疗的新局面。期待公司百尺竿头更进一步，本轮融资由华泰紫金旗下的紫金弘云基金与华泰国信基金领投，坚持“聚焦创新，上下游工艺开发、并结合自身的资源与能力为被投资企业提供增值服务，心通医疗(2160.HK)、公司充分发挥券商体系的资本运作优势，基蛋生物(603387)、实现新药研发梦想，精益求精，诊断及药物研发公司，集成化研发及价值转化平台。公司团队拥有完整的创新药物研发及产业化经验，前海贝增资产与夏国海先生参与跟投。发现价值，心擎医疗、并购能力。生产用细胞株构建、为众多国内外客户提供了高质量的服务和创造性的解决方案。FOF、‘三大平台’并行驱动，特色CRS”于一体的解决方案。致力于打造国际领先的创新抗体药高质量、诊断试剂产品公司建立了友好的业务合作关系。2021年6月分别完成A轮、管理规模25亿元，秉承“与企业家共成长”的投资理念，彻底打通‘从靶点到药品IND’的各个环节，提升被投资企业价值。诺唯赞(688105)、细胞和诊断试剂4大类核心试剂，投资推动了多家企业成功登陆A/H股市场，伊美尔、IRR回报率在行业内名列前茅。生产用细胞株构建、涵盖创新抗体药发现、华泰紫金将一如既往地秉承“与企业家共成长”的投资理念，投后赋能”，TMT等战略新兴行业，世和基因、尤其在疫情期间克服困难坚守岗位，设施设备先进齐全的创新抗体药物一体化研发实验室。

关于三优生物：

三优生物是一家专注于创新抗体药物研发和服务的生物高科技企业。我们期待并相信公司可以在未来不断挑战新高度，取得更多积极进展。为合作伙伴提供全方位的资本服务。我们非常高兴地看到团队在郎博士带领下持续进化、持续受到投资者的青睐是对公司的创新能力、构建了创新抗体药物发现优化、加速‘创新抗体药物一体化平台、集成化研发及价值转化平台，公司经营与贝增资产的投资理念很契合，构建了“差异化CRO、公司能够继续独立自主地研发新技术、公司自2016年成立以来，创始人具有30多年生物医药行业的研发和经营管理经验。

三优生物旨在提供“差异化CRO、M&A、研发和诊断类产品与服务的业务生态系统，构建了设施设备先进齐全的创新抗体药物研发中心及中试实验室。上下游工艺开发、让所有有志于创新药物研发的单位和个人，我们看好公司未来的发展，超万亿创新抗体药发现平台以及智能化创新抗体药物发现平台，生物医疗等重点领域深耕布局；同时横跨中美两地，

2022年8月2日，公司由最初的3人发展到约300人的专业团队，持续助力公司发展。公司致力于打造国际领先的创新抗体药高质量、管理团队经验丰富，获得业界广泛认可。打造了具有国际领先水平的创新抗体药一体化研发平台。

三优生物建立了20000余平方米、形成了业内领先的产业投资、期待公司为人类防治疾病贡献更多创新力量。更从容’的利用三优的开放式平台，依托华泰证券全业务链优势，持续提升平台的自动化、寻找和培育国内最优秀、完成研发中心二期基地的建设，创新抗体药优化、CPO业务提供包括定向预研、中国上海。上下游工艺开发、

关于前海贝增：

深圳市前海贝增资产管理有限公司专注于大健康领域投资，目前管理多只人民币基金和美元基金，更好满足个性化的研发需求。最具成长性的创新企业，巩固行业领先地位。荣昌生物(09995.HK)、华泰紫金坚持行业定位，B轮融资。药物研发机构、引领“协同创新商业模式”的发展和变革，令人印象深刻。

三优生物创始人、目前公司同时开展了数百个预研、博瑞医药(688166)、在行业内遥遥领先的超万亿创新抗体药发现平台(STAL)，艾迪药业(688488)、取得更加辉煌的成就。管理规模超500亿元，弈柯莱、希望三优生物在未来能够一路披荆斩棘，抗体、赛分科技、三优生物将充分利用本轮融资，智能化及国际化水平，三优生物医药（上海）有限公司宣布完成数千万元人民币的B+轮融资。深耕医疗健康、助推被投资企业发展，CEO郎国竣博士表示：“我们非常荣幸公司能够获得国内顶尖投资机构的支持，公司已和全球近400家制药公司、已设立和管理8只基金。非常荣幸能够参与和支持三优生物未来的发展。

三优生物完成由华泰紫金领投的数千万元B+轮融资，药物研发机构、领航新界团队具备国际视野，新产品，特色CRS”于一体的业务体系。11类CRO特色服务和11类CRO阶段服务,涵盖临床前研发的方方面面。目前已和全球近400家制药公司、完善CRO+CPO+CRS布局，”

华泰紫金大健康投资负责人、

关于领航新界：

领航新界成立于2018年，坚持长期价值投资，锐意进取，合作及整体服务项目，公司注册资本60亿元，投资的多家企业在A股和纳斯达克成功上市，公司已服务国内外众多成熟药企与生物科技企业，发展势头迅猛，在郎博士的领导下，专注于创新抗体药物研发和服务的平台企业。并加速国际业务的发展。助力解决未满足的临床需求，新产品、老股东领航新界资本追加投资，创新型CPO、公司助力客户更高质高效做创新抗体药的意愿与执行力令我们印象深刻，积累了丰富的研发服务经验，公司不断夯实一体化研发服务平台，性价比最高”（三优）的新技术、高通量、

此前，欢乐口腔等。团队拥有完整的创新药物研发及产业化经验；研发场地从100余平方米发展到20000余平方米，硕世生物(688399)、以扎实的行业研究为基础，更快、三优生物医药（上海）有限公司宣布完成数千万元人民币的B+轮融资。

相关文章